Research Article

A Novel Established Cuproptosis-Associated LncRNA Signature for Prognosis Prediction in Primary Hepatic Carcinoma

Lan Luo, Xiaoyan Hu, Aoshuang Huang, Xiaofang Liu, Lingyun Wang, Tao Du, Lei Liu, and Ming Li

Department of Hematology and Oncology, The First People’s Hospital of Guiyang, No. 97, Boai Road, Nanming, Guiyang, Guizhou 550002, China

Correspondence should be addressed to Lan Luo; 1621020380@stu.cpu.edu.cn

Received 8 August 2022; Revised 20 August 2022; Accepted 25 August 2022; Published 15 September 2022

Academic Editor: Xueliang Wu

Copyright © 2022 Lan Luo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The copper ion content in the body maintains homeostasis, and when dysregulated, it can produce cytotoxicity and induce cell death through a variety of pathways. Cuproptosis refers to copper ions combining directly with acylated molecules, leading to the accumulation of oligomerization of lipoylated protein and subsequent downregulation of iron-sulfur cluster proteins; this induces proteotoxic stress and cell death. This study on the relationship between cuproptosis-related lncRNAs (CRLRs) and the prognosis of primary hepatic carcinoma (PHC) has important clinical guiding significance for the diagnosis and treatment of PHC. Prognosis-related CRLRs were identified via rank-sum tests, correlational analyses, and univariate Cox regression, and a CRLR risk-scoring model (CRLRSM) was constructed using LASSO Cox regression. Patients were divided into high-risk and low-risk groups based on the median CRLRSM scores. Variance analysis for cuproptosis-related genes, gene set enrichment analysis, and correlational analysis for risk and immunity were performed using boxplots. Quantitative polymerase chain reactions were used to verify the CRLR levels in PHC cell lines. The study results showed that patients in the CRLRSM high-risk group had worse survival rates than those in the low-risk group. The PHC stage and risk score were independent prognostic factors for hepatocellular carcinoma. There were 7 CRLRs (MIR210HG, AC099850.3, AL031985.3, AC012073.1, MKLN1-AS, KDM4A-AS1, and PLBD1-AS1) associated with PHC prognosis, primarily through cellular metabolism, growth, proliferation, apoptosis, and immunity. In conclusion, the overexpression of 7 CRLRs in patients with PHC indicates a poor prognosis.

1. Introduction

Copper ion is an essential metal element for bacteria, animals, and humans, and an indispensable cofactor in the process of life activities [1]. Under normal physiological conditions, copper ions maintain a low concentration in organisms and maintain dynamic balance, and excessive accumulation of copper ions induces cell death [2]. The mechanism is unknown, but in recent years, it has been found that copper ions combine with anticancer drugs to produce reactive oxygen species, form oxidative stress, inhibit antiapoptotic factors, activate apoptosis-related pathways, and thus induce apoptosis of cancer cells [3, 4]. Cu^{2+} complexes can be potent proteasome inhibitors, inhibiting proteasome activity in some tumors and subsequently inhibiting cell proliferation [5, 6]. Recently, Tsvetkov et al. found that copper ions directly bind to the lipoacylated component of the tricarboxylic acid cycle (TCA) in mitochondria respiration, leading to the aggregation of lipoacylated proteins and subsequent downregulation of iron-sulfur cluster proteins, leading to proteotoxic stress and ultimately cell death. Copper carriers were also found to kill specific drug-resistant cancer cells. The research team identified this as a new type of cell death, termed cuproptosis [7].

Primary hepatic carcinoma (PHC) is one of the most common digestive system malignancies and comprises mainly hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). The pathogenesis of PHC is a complex and multistage process, involving epigenetics and
genetics, finally leading to the cancerization of hepatic cells. Although ever-improving surgical approaches and emerging drugs have lengthened patient survival, their overall outcomes remain unsatisfactory. The five-year survival rate in patients with PHC is merely 20% [8].

In order to prolong the survival of patients with Primary hepatic carcinoma, we identified FDX1, LIAS, LIPT1, DLD, DLAT, PDHA1, PDHB, MTF1, GLS, and CDKN2A as cuproptosis-related genes [7] through previous studies. Long noncoding RNAs (lncRNAs) are nonbiased RNAs with a length of more than 200 nucleotides [9]. Accumulating evidence shows that lncRNA plays a complex and precise regulatory role in the process of tumorigenesis and development by acting as oncogenes or tumor performing factors [10–13]. They can not only regulate the proliferation, differentiation, invasion, and metastasis of cancer cells but also regulate the metabolic reprogramming of cancer cells [14–16]. There are currently few studies regarding the correlation between cuproptosis-related lncRNAs and PHC. Therefore, we built a new model of cuproptosis-related lncRNAs to predict the prognoses of PHC patients, assess the predictive performance of these lncRNAs, interpret individual differences, identify targets, and improve survival, which would be of great value in clinical practice.

2. Materials and Methods

2.1. Collection of Gene Expression and Clinical Data. There were 421 sets of public RNA-sequencing transcriptome data and clinical data extracted from UCSC Xena (http://xena.ucsc.edu/); one set of clear cell adenocarcinomas and six sets with unavailable clinical information were excluded. Thus, 414 sets were included: 364 sets of cancer tissue samples and 50 sets of normal tissue samples. HCC and HCC concomitant with ICC were the primary pathological types. The collected clinical characteristics included age, sex, pathological stage, overall cancer stage, survival state, and overall survival (OS) of the patients. Ten cuproptosis-related genes were identified through screening of genome-wide CRISPR–Cas9 deletions [7].

2.2. Cuproptosis-Related lncRNAs. There were 19266 mRNAs and 13431 lncRNAs that were recognized from the cancer tissues and normal tissues using the “Perl” software, and 10 cuproptosis-related genes were identified through screening of genome-wide CRISPR–Cas9 deletions. To assess lncRNAs associated with cuproptosis, Spearman’s rank correlation coefficient was analyzed using the “limma” R package. The lncRNAs with \( p < 0.001 \) and a correlation coefficient of 0.4 were selected as cuproptosis-related lncRNAs. Univariate Cox regression was used to identify 106 prognosis-related lncRNAs (\( p < 0.05 \)).

2.3. Construction of the Prediction Model. The Least Absolute Shrinkage and Selection Operator (LASSO) was processed using the “glmnet” R package to sort out cuproptosis-related lncRNAs (CRLRs), which were then plugged into a multivariate Cox model to construct a CRLR risk-scoring model (CRLRSM). The following formula was used for the risk scoring:

\[
\text{Risk score} = \sum \text{Coef}_{\text{lncRNAs}} \times \text{Exp}_{\text{lncRNAs}}. \tag{1}
\]

Patients were divided into high-risk and low-risk groups based on the median CRLRSM scores.

2.4. Survival Analysis and Model Validation. A total of 364 PHC patients were assigned in a 5:5 ratio to a training \( (n=184) \) or test group \( (n=180) \) for validation of the risk score. Kaplan–Meier analysis was performed, and the area under the receiver operator characteristic (ROC) curve (AUC) was calculated using R (version 4.1.3) for the three groups of low-risk and high-risk patients to estimate the accuracy and sensitivity of the OS prediction. Principal components analysis was used to evaluate differences in the expression of CRLRs in patients with PHC. To evaluate whether the risk score would be an independent prognostic factor and to identify clinical characteristics that could be regarded as independent prognostic factors, ROC univariate analysis, and Cox multivariate analysis were performed for clinical characteristics (age, sex, pathological stage, and overall stage) and the risk score. The ROC was used to compare the predictive performance between the clinical characteristics and risk score.

2.5. Nomogram Predicted Survival. A predictive nomogram for cancer risk can estimate the survival of specific cancer patients based on individual data, and they are of great value in clinical practice [17]. Using the “rms” and “Hmisc” R packages, we plotted a nomogram that included stages and risk scores. The AUC and calibration charts were used to evaluate the predictive accuracy and value of the 1-year, 3-year, and 5-year survival rates. A consistency index (C-index) was used to validate the performance of the nomogram predictions.

2.6. Variance Analysis for Cuproptosis-Related Genes. A boxplot is used to visualize the dispersion of data, which can be used to compare the distribution characteristics of multiple sets of data. Therefore, we constructed a boxplot, using the “limma” and “ggpubr” packages in R to evaluate whether there was a difference in the expression of cuproptosis-related genes between high-risk and low-risk groups.

2.7. Correlational Analysis for Risk and Immunity. The types and distributions of immune cells from the 414 patients were analyzed using the CIBERSORT algorithm, and the relationship between the risk score and the amount of immune cell invasion was assessed using Spearman’s correlation analysis. Statistical significance was indicated by a \( p \) value < 0.05.

2.8. Gene Set Enrichment Analysis. The patients were assigned to the low-risk or high-risk group based on the prediction model. Gene set enrichment analysis was
performed to identify significantly associated biological functions and signaling pathways, which might be potential pathways related to CRLR regulation. Statistical significance was indicated by a false discovery rate (FDR) < 0.05.

2.9. Cell Culturing. Human cell lines of normal hepatocytes (LO-2) and hepatomas (Huh7, Hep3B, and SK-Hep-1) were purchased from the Cell Collection Center of the Chinese Academy of Sciences. All cell lines were incubated in 5% CO2 at 37°C on a medium supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin. LO-2 cells were cultured using RPMI1630 medium, Huh7 cells were cultured using DMEM high-glucose medium, and Hep3B and SK-Hep-1 cells were cultured using MEM high-glucose medium.

2.10. Real-Time Polymerase Chain Reaction (PCR). RNA was extracted from $1 \times 10^6$ LO-2, Huh7, Hep3B, and SK-Hep-1 cells using TRIzol reagent, followed by reverse-transcription to synthesize cDNA using a cDNA synthesis kit according to the manufacturer’s instructions. Based on the SYBR-Green method (TaKaRa), the 7500 Real-Time PCR System (Applied Biosystems) was used to measure the levels of the resulting cDNA. The reaction program was 30 s at 94°C, followed by 40 cycles of 5 s at 94°C and 35 s at 61°C. The primer sequences are shown in Table 1. Differences in the levels of targeted genes between the test and control groups were analyzed via the $2^{-\Delta\Delta Ct}$ method, using the following calculation: $\Delta Ct = C_{\text{target}} - C_{\text{internal reference}}$. The average $\Delta Ct$ of the control group was recorded as the $\Delta Ct_{\text{control average}}$. Subtracting the $\Delta Ct_{\text{control average}}$ from the $\Delta Ct$ of each group yields the $\Delta \Delta Ct$ value, that is, $\Delta \Delta Ct = \Delta Ct_{\text{sample}} - \Delta Ct_{\text{control average}}$. The $2^{-\Delta\Delta Ct}$ value of each group, indicating the relative expression of the genes in the group, was then calculated.

2.11. Data Analysis. PERL (version 5.32.11, https://strawberryperl.com/) was used for gene name translation, lncRNA identification, data-file expression, and phenotyping. All statistical analyses were performed using R software (version 4.1.3) or GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA). A $p$ value < 0.05 indicated statistical significance. All experiments were performed twice.

3. Results

3.1. Data Processing. There were 414 cases of HCC or HCC with ICC downloaded from UCSC Xena; of these, 50 were pericarcinomatous tissues. A total of 13,431 lncRNA were obtained, and 10 cuproptosis-related genes were identified through screening of genome-wide CRISPR–Cas9 deletions (Figure 1(a)). A total of 106 prognosis-related lncRNAs were identified using univariate Cox regression analysis. Seven CRLRs were identified using LASSO Cox regression: MIR210HG, AC099850.3, AL031985.3, C012073.1, MKLN1-AS, KDM4A-AS1, and PLBD1-AS1 (Figures 2(a) and 2(b)).

3.2. Construction and Validation of CRLR Risk Model for PHC. Seven CRLRs were identified via LASSO Cox regression using the following risk-scoring formula:

$$\text{Risk score} = (\text{MIR210HG} \times 0.068) + (\text{AC099850.3} \times 0.017) + (\text{AL031985.3} \times 0.327) + (\text{AC012073.1} \times 0.102) + (\text{MKLN1-AS} \times 0.426) + (\text{KDM4A-AS1} \times 0.152) + (\text{KDM4A-AS1} \times 0.049).$$

The patients were divided in a 5:5 ratio into training and test groups, based on the median scores of the CRLRSVM (Figures 3(a), 3(f), and 3(k)). The whole group is the sum of patients in the training and test groups. The number of deaths increased as the risk score increased (Figures 3(b), 3(g), and 3(l)). A heat map showed that the 7 CRLR genes were related to a poor prognosis (Figures 3(c), 3(h), and 3(m)). There was a significant difference in survival between the high- and low-risk groups in the training group; patients in the low-risk group had longer survival times compared with those in the high-risk group. In the test group as well, patients in the low-risk group had longer survival times than...
Figure 1: (a) Flow chart of the study. (b) Univariate Cox regression analysis results for prognosis-associated lncRNAs.

Figure 2: (a) LASSO cross-validation plot based on seven CRLRs. (b) LASSO coefficient of the seven CRLRs in PHC.
Figure 3: Continued.
3.3. Predictive Nomogram. A predictive nomogram for cancer risk can estimate the survival of specific cancer patients based on individual data. Based on multivariate Cox regression, the overall stage and risk score were included to construct the nomogram (Figure 6(a)). The whole group was internally validated using the C-index (Figure 6(b)). The 1-year, 3-year, and 5-year AUCs of the nomogram were 0.766, 0.716, and 0.693, respectively, suggesting that the nomogram had excellent specificity and sensitivity for predicting the OS time (Figure 6(c)). The calibrated nomogram was consistent with the diagonal, indicating the predictive value of the nomogram for 1-year, 3-year, and 5-year OS (Figure 6(d)). These results demonstrated that the CRLRSM-based nomogram had good prediction performance for the prognoses of patients with PHC.

3.4. Enrichment Analysis of Function Pathway Sets. Boxplots were used to analyze the FDX1, CDKN2A, MTF1, and GLS genes of the patients in the two groups. FDX1 expression levels in the low-risk group of patients were significantly increased (Figure 7(a), \( p < 0.001 \)); CDKN2A, GLS, and MTF1 expression levels were significantly increased in the high-risk group of patients (Figures 7(b)–7(d), \( p < 0.001 \)). This shows that PHC patients with high expression of FDX1 had better prognoses, whereas those with high expression of CDKN2A, MTF1, and GLS had worse prognoses. We conducted gene set enrichment analysis to explore the potential biological functions and signaling pathways between the two groups. There were 52 active pathways in the high-risk group (Figure 8(a)), FDR < 0.05. The enrichment pathways were associated with cellular metabolism, repair, growth, proliferation, apoptosis, and immunity. There were 2 active pathways related to
tricarboxylic acid metabolism in the low-risk group (Figure 8(a), FDR < 0.05).

3.5. Correlation between Prognostic Risk Scores and Immune Cells. The CIBERSORT algorithm was used to analyze 22 different immune cells for the two groups of patients. There were positive correlations between the risk score and M0 macrophages ($R = 0.36$, $p = 8.1 \times 10^{-10}$), neutrophils ($R = 0.15$, $p = 0.015$), and follicular helper T cells ($R = 0.23$, $p = 9.3 \times 10^{-05}$) (Figures 9(a)–9(c)). Negatively correlations were found between the risk score and resting mast cells ($R = -0.23$, $p = 9.9 \times 10^{-05}$), monocytes ($R = -0.14$, $p = 0.018$), activated natural killer (NK) cells ($R = -0.13$, $p = 0.027$), CD8 T cells ($R = -0.12$, $p = 0.046$), gamma delta T cells ($R = -0.19$, $p = 0.0013$), and naive B cells ($R = -0.12$, $p = 0.038$) (Figures 9(d)–9(i)). This indicates that PHC prognosis is associated with immune cell infiltration.

3.6. Overexpression of MIR210HG, MKLN1-AS, and PLBD1-A in PHC Patients. The expression levels of the seven CRLRs in liver cancer cells and normal hepatocytes were measured using PCR. The results showed that MIR210HG, MKLN1-AS, and PLBD1-AS were overexpressed in liver cancer cells (Figures 10(a)–10(c)); the expression of the other four CRLRs was decreased. This might be attributed to the variances among the different cell lines and false-positive results of the prediction (Figure 10(d)).

4. Discussion

Cell death is a physiological process. The mechanism of cell death varies. Apoptosis [18], pyroptosis [19], necrosis [20], and ferroptosis [21–23] are the most commonly observed. Recently, Tsvetkov et al. found a copper-based mechanism that was completely different from the known mechanisms of cell death, and they named it “cuproptosis” [7]. LncRNAs

Figure 4: The high-risk and low-risk groups are analyzed using (a) the whole geneset, (b) the cuproptosis geneset, (c) the cuproptosis lncRNA set, and (d) the cuproptosis risk lncRNA set.
Figure 5: (a) Univariate Cox regression showing that the age, stage, and risk score are associated with OS in the training cohort ($p < 0.05$). (b) Multivariate Cox regression shows that the stage and risk score ($p < 0.05$) are independent prognostic indicators of OS in patients with PHC in the training cohort. (c) ROC curve shows that the stage and risk score have the highest prognostic accuracy in the training cohort. (d) Univariate Cox regression shows that the stage and risk score are associated with OS in the testing cohort ($p < 0.01$). (e) Multivariate Cox regression shows that the stage and risk score ($p < 0.05$) are independent prognostic indicators of OS in patients with PHC in the testing cohort. (f) ROC curve shows that the stage and risk score have the highest prognostic accuracy in the testing cohort. (g) ROC curve shows that the stage and risk score have the highest prognostic accuracy for the entire cohort.
have been shown to be associated with hepatic carcinoma [24, 25]. Therefore, we built a cuproptosis-related IncRNA prognostic risk model to predict the prognoses of patients with PHC, explore its potential pathogenesis, and facilitate individualized treatment.

Hepatoma tissue samples were divided into CRLRSM high-risk and low-risk groups. The OS of patients in the high-risk group was worse than that of patients in the low-risk group. The CRLRSM was an independent prognostic factor for PHC and had a good predictive performance for the prognoses of patients with PHC. Correlation analyses between the CRLRSM and cuproptosis-related genes showed that patients with high FDX1 expression had better prognoses, indicating that high expression of FDX1 might promote cancer cell death. Patients with high expression of CDKN2A, MTF1, and GLS had worse prognoses, suggesting that CDKN2A, MTF1, and GLS might promote the proliferation of cancer cells. This is consistent with the findings of Tsvetkov et al. [7], who identified FDX1 as a key regulator of cuproptosis and an upstream regulator of protein lipoacylation, and the abundance of FDX1 and lipoacylated proteins is highly correlated with a variety of human tumors. The results also suggest that CDKN2A, MTF1, and GLS are negative feedback genes that inhibit apoptosis and promote cell survival. At the same time, the enrichment pathway of the CRLRSM high-risk group was related to tumor cell genesis and proliferation. The enrichment pathway of the CRLRSM low-risk group was mainly related to the tricarboxylic acid cycle, and was mainly in the upstream pathway entering the tricarboxylic acid cycle, indicating that the progress of the tricarboxylic acid cycle was blocked. Therefore, these seven CRLns may be potential targets for the treatment of PHC.

We validated the expression of the seven CRLRs in hepatic cancer cells and normal hepatocytes and found that MIR210HG, MKLN1-AS, and PLBD1-AS were highly overexpressed in hepatic cancer cells. Recent studies have shown that overexpression of MKLN1-AS is associated with a lower OS rate and shorter disease-free survival. The downregulation of MKLN1-AS reduces the proliferation, migration, and invasion of cancer cells and induces apoptosis. In vivo inhibition can also suppress the proliferation...
of hepatic cancer cells. MKLN1-AS has been shown to serve as a molecular sponge for miR-654-3p, upregulate the expression of HCC-derived growth factor (HDGF), and promote cancer growth [26]. The upregulation of MKLN1-AS also leads to poor prognoses in patients with PHC. MKLN1-AS positively regulates the expression of YAP1 via targeting and stabilizing YAP1 mRNA, and it enhances the proliferation, migration, and invasion of hepatic cancer cells through YAP1. It can also induce the expression of YAP1 in vivo to cause hepatic carcinogenesis [27].

MIR210H was first found to be overexpressed in osteosarcoma and glioma. Wang et al. discovered that hepatic cancer cells overexpressing MIR210H contributed to poor prognoses in patients, whereas silencing MIR210H inhibited proliferation, migration, and invasion of cancer cells [28]. AC099850.3 and KDM4A-AS1 are newly identified lncRNAs, and their overexpression indicates an adverse prognosis in PHC patients. Knockout of AC099850.3 might significantly inhibit the proliferative and migratory potential of hepatic cancer cells and promoted their death. A previous study proposed that AC099850.3 served as an oncogene through the PRR11/P13K/AKT pathway [29]. KDM4A-AS1 promotes the proliferation, migration, and invasion of hepatic cancer cells in vitro and promotes the growth of hepatic cancer cells and lung metastasis in vivo. It is suggested that KDM4A-AS1 is regulated retrograde by miR-411-5p at the post-transcriptional level and promotes the expression of KPNA2 by competitively binding to miR-411-5p to activate the AKT pathway. KPN2 silencing, miR-411-5p overexpression, and AKT inhibitors (e.g., MK2206) can reverse KDM4A-AS1-enhanced hepatoma cell proliferation, migration, and epithelial-mesenchymal transformation. KDM4A-AS1 is considered to be a new hypoxia response gene that promotes the growth and metastasis of hepatic cancer [30] through KDM4A-AS1/KPNA2/HIF-1α signaling.

Gene set enrichment analysis showed that the mTOR, p53, ErbB, and insulin signaling pathways, ubiquitin-mediated proteolysis, inositol phosphate metabolism, and the phosphatidylinositol signaling system were associated with the metabolism, growth, proliferation, and apoptosis of cancer cells. The ubiquitin-proteasome system (UPS) had the strongest correlation. The UPS is a multicomponent system for protein degradation in cells and is involved in multiple cellular biological activities such as cell growth and differentiation, DNA replication and repair, cellular

Figure 7: Different expression of (a) FDX1, (b) CDKN2A, (c) GLS, and (d) MTF1 in the high- and low-risk groups.
Evidence-Based Complementary and Alternative Medicine

| IncRNA set name                                | NES   | NOM p-val | FDR q-val |
|------------------------------------------------|-------|-----------|-----------|
| KEGG_UBIQUITIN_MEDIATED_PROTEOLYSIS            | 1.947 | 0.000     | 0.014     |
| KEGG_NUCLEOTIDE_EXCISION_REPAIR               | 1.951 | 0.000     | 0.015     |
| KEGG_PURINE_METABOLISM                        | 1.953 | 0.000     | 0.017     |
| KEGG_BASE_EXCISION_REPAIR                     | 1.849 | 0.002     | 0.018     |
| KEGG_SPHINGOLIPID_METABOLISM                  | 1.852 | 0.000     | 0.018     |
| KEGG_NON_SMALL_CELL_LUNG_CANCER              | 1.898 | 0.000     | 0.011     |
| KEGG_DNA_REPLICATION                          | 1.840 | 0.000     | 0.018     |
| KEGG_PYRIMIDINIC_METABOLISM                   | 1.967 | 0.000     | 0.019     |
| KEGG_VASOPRESSIN_REGULATED_WATER_REABSORPTION | 1.853 | 0.004     | 0.019     |
| KEGG_ENDOMETRIAL_CANCER                       | 1.905 | 0.002     | 0.019     |
| KEGG_INOSITOL_PHOSPHATIC_METABOLISM           | 1.864 | 0.000     | 0.019     |
| KEGG_RNA_POLYMERASE                           | 1.857 | 0.000     | 0.019     |
| KEGG_HOMOLOGOUS_RECOMBINATION                 | 1.916 | 0.000     | 0.019     |
| KEGG_ERBB_SIGNALING_PATHWAY                   | 1.865 | 0.000     | 0.019     |
| KEGG_BASAL_TRANSCRIPTION_FACTORS              | 1.832 | 0.002     | 0.020     |
| KEGG_GLIOMA                                   | 1.866 | 0.000     | 0.020     |
| KEGG_PROGESTERONC_MEDIATED_OOCYTE_MATURATION  | 1.872 | 0.000     | 0.020     |
| KEGG_MISMATCH_REPAIR                          | 1.882 | 0.000     | 0.021     |
| KEGG_CHRONIC_MYOELID_LEUKEMIA                 | 1.874 | 0.002     | 0.021     |
| KEGG_INSULIN_SIGNALING_PATHWAY                | 1.824 | 0.002     | 0.021     |
| KEGG_ENDOCYTOSIS                              | 1.918 | 0.000     | 0.021     |
| KEGG_OOCYTE_MEIOSIS                           | 1.978 | 0.000     | 0.022     |
| KEGG_SPICIOSOME                               | 1.817 | 0.006     | 0.022     |
| KEGG_ADHERENS_FUNCTION                        | 1.791 | 0.006     | 0.025     |
| KEGG_BLADDER_CANCER                           | 1.797 | 0.004     | 0.025     |
| KEGG_SNARE_INTERACTIONS_IN_VESICULAR_TRANSPORT| 1.800 | 0.004     | 0.025     |
| KEGG_PANCREATIC_CANCER                        | 1.803 | 0.002     | 0.025     |
| KEGG_PATHWAYS_IN_CANCER                       | 1.803 | 0.006     | 0.026     |
| KEGG_PHOSPHATIDYLNOSITOL_SIGNALING_SYSTEM     | 1.776 | 0.002     | 0.028     |
| KEGG_P53_SIGNALING_PATHWAY                    | 1.779 | 0.000     | 0.029     |
| KEGG_RNA_DEGRADATION                          | 1.988 | 0.000     | 0.029     |
| KEGG_PROSTATE_CANCER                          | 1.767 | 0.008     | 0.030     |
| KEGG_LYSOSOME                                 | 1.752 | 0.018     | 0.032     |
| KEGG_MTOR_SIGNALING_PATHWAY                   | 1.751 | 0.002     | 0.033     |
| KEGG_N_GLYCAN_BIOSYNTHESIS                    | 1.755 | 0.014     | 0.033     |
| KEGG_COLORECTAL_CANCER                        | 1.746 | 0.004     | 0.034     |
| KEGG_RIG1_LIKE_ReCEPTOR_SIGNALING_PATHWAY      | 1.743 | 0.008     | 0.034     |
| KEGG_THYROID_CANCER                           | 1.739 | 0.004     | 0.035     |
| KEGG_NEUROTROPHIN_SIGNALING_PATHWAY           | 1.734 | 0.006     | 0.036     |
| KEGG_ACUTE_MYOELID_LEUKEMIA                   | 1.732 | 0.008     | 0.037     |
| KEGG_REGULATION_OF_AUTOPHAGY                  | 1.727 | 0.009     | 0.037     |
| KEGG_SMALL_CELL_LUNG_CANCER                  | 1.728 | 0.014     | 0.037     |
| KEGG_SELENOAMINO_ACID_METABOLISM              | 1.719 | 0.008     | 0.038     |
| KEGG_REGULATION_OF_ACTIN_CYTOSKELETON         | 1.720 | 0.010     | 0.039     |
| KEGG_CYTOSOLIC DNA-SENSING_PATHWAY            | 1.715 | 0.016     | 0.039     |
| KEGG_LYSINE_DEGRADATION                       | 1.701 | 0.014     | 0.042     |
| KEGG_PC_GAMMA_R_MEDIATED_PHAGOCYTOSIS          | 1.703 | 0.008     | 0.042     |
| KEGG_MELANOMEGENESIS                          | 1.690 | 0.002     | 0.043     |
| KEGG_CELL_CYCLE                               | 2.021 | 0.000     | 0.044     |
| KEGG_RENAL_CELL_CARCINOMA                    | 1.690 | 0.010     | 0.045     |
| KEGG_HUNTINGTONS_DISEASE                     | 1.685 | 0.029     | 0.046     |
| KEGG_VIBRIO_CHOLERA_INFECTION                 | 1.679 | 0.018     | 0.047     |

| IncRNA set name                                | NES   | NOM p-val | FDR q-val |
|------------------------------------------------|-------|-----------|-----------|
| KEGG_PRIMARY_BILE_Acid_BIOSYTH                 | -1.88642 | 0         | 0.025761865 |
| KEGG_FATTY_Acid_METABOLISM                     | -1.89435 | 0.00203252 | 0.035317067 |

NES, normalized enrichment score; NOM, nominal; FDR, false discovery rate.

(a)

(b)

Figure 8: CRLRs set enrichment analysis for the (a) high-risk group and (b) low-risk group.

metabolism, and the immune response, affecting the degradation of most proteins in eukaryotic cells [31]. UPS dysfunction has been found to be closely related to multiple diseases, including neurodegenerative diseases, cancer, cardiovascular diseases, and respiratory diseases [32].

UPS dysfunctions can be divided into two categories based on specific mechanisms. The first involves genetic mutation of the enzymes or substrates of the UPS system, in which normal UPS targets are no longer subject to ubiquitinated and degraded; subsequently, they constantly accumulate in the cells. The second category is abnormal activation of the UPS, which accelerates the degradation of intracellular proteins. There are also UPS inhibitors, such as bortezomib, which inhibit the catalytic activity of the proteasome subunits, resulting in mitochondrial membrane depolarization and cell apoptosis. Apoptosis is induced mainly by an increase in intracellular p27 and p53 levels [33]. Second-generation proteasome inhibitors, including kafitomib and oral isazomib, are used for the treatment of multiple myeloma. TP53 encodes a transcription factor, and the tumor suppressor p53 is activated and stabilized simultaneously in response to cellular stress and DNA
damage; this is the basis for its central role as a tumor suppressor [34, 35].

It has been found that the MDM2 gene is expressed in the UPS and p53 signal pathways. MDM2 inhibits p53-induced apoptosis and is the most connected functional target of p53. Its N-terminal domain binds to the transcriptional activation domain of p53, hinders the binding of p53 to its cotranscriptional activators, and subsequently inhibits the activation of p53 target genes [36]. The RING domain in the C-terminus of MDM2 has E3 ubiquitin ligase activity and can ubiquitinate and degrade p53 [37]. In some human tumors, MDM2 has been demonstrated to be upregulated abnormally due to gene magnification, increased transcription, and enhanced translation; these would induce increased degradation and decreased activity of p53 [38]. Based on the strategy of blocking the protein interaction between p53 and MDM2, some small molecules have been developed, including BI-907828 [39], milademetan [40], and APG-115 [41]. Among these agents, APG-115 and milademetan have been approved for clinical trials and have yielded preliminary clinical data [42, 43]. Upregulation of the phosphocreatine kinase signal pathway, insulin signal pathway, and ErbB signal pathway can activate the PI3K/AKT pathway and mTOR, which plays a critical role in the

Figure 9: Relationships between the CRLRs and infiltration abundances of nine types of immune cells, as analyzed using Spearman’s correlation analysis. (a) M0 macrophages; (b) neutrophils; (c) follicular helper T cells; (d) resting mast cells; (e) monocytes; (f) activated NK cells; (g) CD8+ T cells; (h) gamma delta T cells; (i) naive B cells.
regulation of autophagy [44]. The mTOR signal is highly activated in most cancers, especially in the process of cell transformation, growth, and survival [45].

The correlations between risk scores and immune cells showed that immune cell infiltration is associated with the prognosis of PHC. Several enriched pathways were associated with the immune response. For example, the ErbB pathway downregulates the chemokine ligand CXCL10 through PI3K–AKT signaling and interferon regulatory factor IRF1, which results in the reduction of effector CD8+ T cells and recruitment of Treg cells into the tumor microenvironment; this leads to immune escape and cancer growth [46]. PI3K–AKT–mTOR regulates many characteristics of the immunosuppressive microenvironment. The latest data from clinical trials and preclinical mouse models suggest that the therapeutic inhibition of the PI3K–AKT–mTOR signaling network might have dual benefits: preventing tumor progression by suppressing proliferation, migration, and survival of cancer cells, and enhancing the tumor immune surveillance pathway and intrinsic antitumor immune characteristics by inhibiting the activation of immunosuppressants [47]. Shishir et al. believed that the tumor microenvironment of HCC still remains a major challenge to therapeutic success. To explore a new strategy of combined immunotherapy will hopefully lead to major improvements in survival for patients [48].

In conclusion, hepatic carcinogenesis is a complicated process that involves multiple biological functions and pathways. This often results in unsatisfactory therapeutic outcomes and poor survival rates in patients with PHC. The seven CRLns in the high-risk group were found to be involved in multiple pathways to promote the growth, proliferation, invasion, and migration of PHC. The low-risk group was involved in multiple pathways related to the tricarboxylic acid cycle, therefore, silencing the seven CRLNs may promote tumor cell death, which is a potential target for the treatment of PHC, and further research is needed to verify its mechanism and efficacy in the future. This study has several limitations. First, the data were obtained from the UCSC Xena public database, which has a limited sample size. Second, we did not explore further functional genomics and pathways, although we assessed the expression of CRLR in hepatoma cells and normal hepatocytes. Lastly, our study lacks further validation from cohort, prospective, multi-center, and real data.

** Figure 10:** The results of RT-qPCR for (a) MIR210HG, (b) MKLN1-AS, and (c) PLBD1-AS in the hepatoma cell lines. (d) The results of RT-qPCR for the seven CRLRs in the hepatoma cell lines. **p < 0.01. **
Data Availability

The raw data could be obtained from the corresponding author.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] B. E. Kim, T. Nevitt, and D. J. Thiele, “Mechanisms for copper acquisition, distribution and regulation,” Nature Chemical Biology, vol. 4, no. 3, pp. 176–185, 2008.

[2] T. D. Rae, P. J. Schmidt, R. A. Pufahl, V. C. Culotta, and T. O’Halloran, “Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase,” Science, vol. 284, no. 5415, pp. 805–808, 1999.

[3] K. Shimada, E. Reznik, M. E. Stokes et al., “Copper-binding small molecule induces oxidative stress and cell-cycle arrest in glioblastoma-patient-derived cells,” Cell Chemical Biology, vol. 25, no. 5, pp. 585–594, 2018.

[4] N. C. Yip, I. S. Fombon, P. Liu et al., “Disulfiram modulated ROS-MAPK and NF-κB pathways and targeted breast cancer cells with cancer stem cell-like properties,” British Journal of Cancer, vol. 104, no. 10, pp. 1564–1574, 2011.

[5] D. Chen, Q. C. Cui, H. Yang, and Q. P. Dou, “Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity,” Cancer Research, vol. 66, no. 21, pp. 10425–10433, 2006.

[6] Z. Skrott, M. Mistrik, K. K. Andersen et al., “Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4,” Nature, vol. 552, no. 7684, pp. 194–199, 2017.

[7] P. Tsvetkov, S. Coy, B. Petrova et al., “Copper induces cell death by targeting lipoylated TCA cycle proteins,” Science, vol. 375, no. 6586, pp. 1254–1261, 2022.

[8] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer statistics, 2022,” CA: A Cancer Journal for Clinicians, vol. 72, no. 1, pp. 7–33, 2022.

[9] A. Bhan, M. Soleimani, and S. S. Mandal, “Long noncoding RNA and cancer: a new paradigm,” Cancer Research, vol. 77, no. 15, pp. 3965–3981, 2017.

[10] Y. Li, J. Zou, B. Li, and J. Du, “Anticancer effects of metilavon via regulating lncRNA JRX-Wnt/β-catenin signalling pathway in human osteosarcoma cells,” Journal of Cellular and Molecular Medicine, vol. 25, no. 20, pp. 9545–9556, 2021.

[11] L. Yang, Y. Li, R. Gong et al., “The long non-coding RNA-ORLNC1 regulates bone mass by directing mesenchymal stem cell fate,” Molecular Therapy, vol. 27, no. 2, pp. 394–410, 2019.

[12] R. Esposito, N. Bosch, A. Lanzós, T. Polidori, C. Pulido-Quetglas, and R. Johnson, “Hacking the cancer genome: profiling therapeutically actionable long non-coding RNAs using CRISPR-cas9 screening,” Cancer Cell, vol. 35, no. 4, pp. 545–557, 2019.

[13] J. Kim, H. L. Piao, B. J. Kim et al., “Long noncoding RNA MALAT1 suppresses breast cancer metastasis,” Nature Genetics, vol. 50, no. 12, pp. 1705–1715, 2018.

[14] J. D. Ransohoff, Y. Wei, and P. A. Khavari, “The functions and unique features of long intergenic non-coding RNA,” Nature Reviews Molecular Cell Biology, vol. 19, no. 3, pp. 143–157, 2018.

[15] M. Huarte, “The emerging role of IncRNAs in cancer,” Nature Medicine, vol. 21, no. 11, pp. 1253–1261, 2015.

[16] J. Luo, L. F. Langer, and J. Liu, “A novel role of LncRNA in regulating tumor metabolism and angiogenesis under hypoxia,” Cancer Communications, vol. 39, no. 1, p. 2, 2019.

[17] S. Y. Park, “Nomogram: an analogue tool to deliver digital knowledge,” The Journal of Thoracic and Cardiovascular Surgery, vol. 155, no. 4, p. 1793, 2018.

[18] X. Yao, C. Sun, B. Fan et al., “Neotropin exerts neuroprotective effects after spinal cord injury by inhibiting apoptosis and modulating cytokines,” Journal of Orthopaedic Translation, vol. 26, pp. 74–83, 2021.

[19] Z. Rao, Y. Zhu, P. Yang et al., “Pyroptosis in inflammatory diseases and cancer,” Theranostics, vol. 12, no. 9, pp. 4310–4329, 2022.

[20] F. Yang, Y. Li, G. Yan et al., “Inhibition of iron overload-induced apoptosis and necrosis of bone marrow mesenchymal stem cells by melatonin,” Oncotherapy, vol. 8, no. 19, pp. 31626–31637, 2017.

[21] S. Q. Feng, X. Yao, Y. Zhang et al., “Deferoxamine promotes recovery of traumatic spinal cord injury by inhibiting ferroptosis,” Neuronal Regeneration Research, vol. 14, no. 3, pp. 532–541, 2019.

[22] Y. Zhang, C. Sun, C. Zhao et al., “Ferroptosis inhibitor SRS 16-86 attenuates ferroptosis and promotes functional recovery in contusion spinal cord injury,” Brain Research, vol. 1706, pp. 48–57, 2019.

[23] J. Li, J. Zhang, S. Tao, J. Hong, Y. Zhang, and W. Chen, “Prognostication of pancreatic cancer using the cancer genome atlas based ferroptosis-related long non-coding RNAs,” Frontiers in Genetics, vol. 13, Article ID 838021, 2022.

[24] T. Guo, C. Gong, P. Wu et al., “LINC00662 promotes hepatocellular carcinoma progression via altering genomic methylation profiles,” Cell Death & Differentiation, vol. 27, no. 7, pp. 2191–2205, 2020.

[25] A. Xia, W. Yuan, Q. Wang et al., “The cancer-testis IncRNA Inc-CTHCC promotes hepatocellular carcinogenesis by binding hnrNRP K and activating YAP1 transcription,” Naturaliste Canadian, vol. 3, no. 2, pp. 203–218, 2022.

[26] W. Gao, X. Chen, W. Chi, and M. Xue, “Long non-coding RNA MKLN1-AS aggravates hepatocellular carcinoma progression by functioning as a molecular sponge for miR-654-3p, thereby promoting hepatoma-derived growth factor expression,” International Journal of Molecular Medicine, vol. 46, no. 5, pp. 1743–1754, 2020.

[27] C. Guo, S. Zhou, W. Yi et al., “Long non-coding RNA muskelin 1 antisense RNA (MKLN1-AS) is a potential diagnostic and prognostic biomarker and therapeutic target for hepatocellular carcinoma,” Experimental and Molecular Pathology, vol. 120, Article ID 10638, 2021.

[28] Y. Wang, W. Li, X. Chen, Y. Li, P. Wen, and F. Xu, “MIR210HG predicts poor prognosis and functions as an oncogenic IncRNA in hepatocellular carcinoma,” Biomedicine & Pharmacotherapy, vol. 111, pp. 1297–1301, 2019.

[29] F. Zhong, S. Liu, D. Hu, and L. Chen, “IncRNA AC099850.3 promotes hepatocellular carcinoma proliferation and invasion through PRR11/P13K/AKT axis and is associated with patients prognosis,” Journal of Cancer, vol. 13, no. 3, pp. 1048–1060, 2022.

[30] T. Chen, R. Liu, Y. Niu et al., “HIF-1α-activated long non-coding RNA KDM4A-AS1 promotes hepatocellular carcinoma progression via the miR-411-5p/KPNA2/AKT pathway,” Cell Death & Disease, vol. 12, p. 1152, 2021.

[31] A. Hershko and A. Ciechanover, “The ubiquitin system,” Annual Review of Biochemistry, vol. 67, no. 1, pp. 425–479, 1998.
A. H. P. Jansen, E. A. J. Reits, and E. M. Hol, “The ubiquitin proteasome system in glia and its role in neurodegenerative diseases,” *Frontiers in Molecular Neuroscience*, vol. 7, p. 73, 2014.

P. Robak and T. Robak, “Bortezomib for the treatment of hematologic malignancies: 15 years later,” *Drugs in R & D*, vol. 19, no. 2, pp. 73–92, 2019.

B. Vogelstein, D. Lane, and A. J. Levine, “Surfing the p53 network,” *Nature*, vol. 408, no. 6810, pp. 307–310, 2000.

A. C. Joerger and A. R. Fersht, “The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches,” *Annual Review of Biochemistry*, vol. 85, no. 1, pp. 375–404, 2016.

C. A. Brady, D. Jiang, S. S. Mello et al., “Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression,” *Cell*, vol. 145, no. 4, pp. 571–583, 2011.

O. Laptenko, I. Shiff, W. Freed-Pastor et al., “The p53 C terminus controls site-specific DNA binding and promotes structural changes within the central DNA binding domain,” *Molecular Cell*, vol. 57, no. 6, pp. 1034–1046, 2015.

J. Momand, D. Jung, S. Wilczynski, and J. Niland, “The MDM2 gene amplification database,” *Nucleic Acids Research*, vol. 26, no. 15, pp. 3453–3459, 1998.

L. Skalniak, E. Surmiak, and T. A. Holak, “A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018),” *Expert Opinion on Therapeutic Patents*, vol. 29, no. 3, pp. 151–170, 2019.

V. Arnhold, K. Schmelz, J. Proba et al., “Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma,” *Oncotarget*, vol. 9, no. 2, pp. 2304–2319, 2018.

A. Aguilar, J. Lu, L. Liu et al., “Discovery 4-(3′R,4′S,5′R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5″-carboxamido)bicyclo[2.2.2]octane-1-carboxylic acid (AA-115/APG-115): a potent and orally active murine double minute 2 (MDM2) inhibitor in clinical development,” *Journal of Medicinal Chemistry*, vol. 60, pp. 2819–2839, 2017.

D. W. Rasco, N. J. Lakhani, Y. Li et al., “A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors,” *Journal of Clinical Oncology*, vol. 37, no. 15, p. 3126, 2019.

T. M. Bauer, M. M. Gounder, A. M. Weise et al., “A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/dedifferentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L),” *Journal of Clinical Oncology*, vol. 36, no. 15, Article ID 11514, 2018.

R. A. Saxton and D. M. Sabatini, “mTOR signaling in growth, metabolism, and disease,” *Cell*, vol. 169, no. 2, pp. 361–371, 2017.

D. Mossmann, S. Park, and M. N. Hall, “mTOR signalling and cellular metabolism are mutual determinants in cancer,” *Nature Reviews Cancer*, vol. 18, no. 12, pp. 744–757, 2018.

S. Kumagai, S. Koyama, and H. Nishikawa, “Antitumour immunity regulated by aberrant ERBB family signalling,” *Nature Reviews Cancer*, vol. 21, no. 3, pp. 181–197, 2021.

G. Xue, A. Zippelius, A. Wicki et al., “Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy,” *JNCI Journal of the National Cancer Institute*, vol. 107, no. 7, p. djv171, 2015.

S. Shetty, A. Lujambio, and F. Tacke, “Editorial: overcoming the immune microenvironment of hepatocellular cancer,” *Frontiers in Immunology*, vol. 12, Article ID 707329, 2021.